NT-proBNP measurement fails to reliably identify subclinical hypertrophic cardiomyopathy in Maine Coon cats

Journal of Feline Medicine and Surgery

Volumn 12, Issue 12, 2010, Pages 942-947

  Singh, Manreet K ^a   Cocchiaro, Michael F ^a   Kittleson, Mark D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CAT; CAT DISEASE; EVALUATION; FEMALE; HOSPITALIZATION; HYPERTROPHIC CARDIOMYOPATHY; MALE; MASS SCREENING; METHODOLOGY; SENSITIVITY AND SPECIFICITY;

ANIMALS; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; CAT DISEASES; CATS; FEMALE; MALE; MASS SCREENING; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 78649712950     PISSN: 1098612X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfms.2010.08.004     Document Type: Article

References (17)

1. van Kimmenade R.R., Januzzi J.L. The evolution of the natriuretic peptides - current applications in human and animal medicine. J Vet Cardiol 2009, 11(suppl 1):S9-21.
2. Fonarow G.C., Peacock W.F., Phillips C.O., Givertz M.M., Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007, 49:1943-1950.
3. Worster A., Balion C.M., Hill S.A., et al. Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review. Clin Biochem 2008, 41:250-259.
4. Hsu A., Kittleson M.D., Paling A. Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy. J Vet Cardiol 2009, 11(suppl 1):S63-S70.
5. Fox P.R., Oyama M.A., Reynolds C., et al. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. J Vet Cardiol 2009, 11(suppl 1):S51-S61.
6. Connolly D.J., Soares Magalhaes R.J., Fuentes V.L., et al. Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. J Vet Cardiol 2009, 11(suppl 1):S41-S50.
7. Connolly D.J., Magalhaes R.J., Syme H.M., et al. Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med 2008, 22:96-105.
8. Meurs K.M., Sanchez X., David R.M., et al. A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. Hum Mol Genet 2005, 14:3587-3593.
9. Meurs K.M., Norgard M.M., Ederer M.M., Hendrix K.P., Kittleson M.D. A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy. Genomics 2007, 90:261-264.
10. MacLean H.N., Abbott J.A., Ward D.L., Huckle W.R., Sisson D.D., Pyle R.L. N-terminal atrial natriuretic peptide immunoreactivity in plasma of cats with hypertrophic cardiomyopathy. J Vet Intern Med 2006, 20:284-289.
11. Hori Y., Yamano S., Iwanaga K., et al. Evaluation of plasma C-terminal atrial natriuretic peptide in healthy cats and cats with heart disease. J Vet Intern Med 2008, 22:135-139.
12. Herndon W.E., Kittleson M.D., Sanderson K., et al. Cardiac troponin I in feline hypertrophic cardiomyopathy. J Vet Intern Med 2002, 16:558-564.
13. Prosek R., Sisson D.D., Oyama M.A., Biondo A.W., Solter P.E. Measurements of plasma endothelin immunoreactivity in healthy cats and cats with cardiomyopathy. J Vet Intern Med 2004, 18:826-830.
14. Kim S.W., Park S.W., Lim S.H., et al. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin Cardiol 2006, 29:155-160.
15. Arteaga E., Araujo A.Q., Buck P., Ianni B.M., Rabello R., Mady C. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 2005, 150:1228-1232.
16. Efthimiadis G.K., Hitoglou-Makedou A., Giannakoulas G., et al. Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy. Heart Vessels 2007, 22:322-327.
17. Kienle R.D. Feline cardiomyopathy. Manual of canine and feline cardiology 2008, 158. Saunders, Elsevier, St Louis, Missouri. L.P. Tilley, F.W.K. Smith, M.A. Oyama, M.M. Sleeper (Eds.).